圣湘生物
(688289)
| 流通市值：99.37亿 | | | 总市值：99.37亿 |
| 流通股本：5.79亿 | | | 总股本：5.79亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 437,346,014.85 | 1,641,533,008.19 | 1,244,138,989.62 | 868,620,485.26 |
| 营业收入 | 437,346,014.85 | 1,641,533,008.19 | 1,244,138,989.62 | 868,620,485.26 |
| 二、营业总成本 | 373,874,252.96 | 1,396,281,013.98 | 1,066,909,188.78 | 702,919,097.81 |
| 营业成本 | 116,708,807.49 | 397,479,157.73 | 336,216,232.56 | 232,065,994.95 |
| 税金及附加 | 2,550,902.27 | 11,532,986.16 | 8,268,826.66 | 5,360,228.15 |
| 销售费用 | 149,057,410.58 | 601,703,210.65 | 422,305,101.98 | 276,486,681.39 |
| 管理费用 | 56,725,333.44 | 220,526,563.06 | 170,598,896.59 | 104,996,177.22 |
| 研发费用 | 56,531,896.35 | 229,114,830.76 | 178,841,044.52 | 118,560,953.24 |
| 财务费用 | -7,700,097.17 | -64,075,734.38 | -49,320,913.53 | -34,550,937.14 |
| 其中:利息费用 | 6,593,760.65 | 23,291,424.56 | 17,569,902.1 | 11,439,504.39 |
| 其中:利息收入 | 16,947,202.72 | 86,818,264.87 | 65,576,635.78 | 45,280,372.46 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 613,304.28 | 48,574,301.3 | 47,982,843.43 | 47,493,750.56 |
| 加:投资收益 | -7,360,567.49 | -55,237,813 | -38,755,321.07 | -24,953,300.33 |
| 资产处置收益 | -2,244,233.13 | -2,946,565.51 | -4,351,330.5 | -3,044,178.72 |
| 资产减值损失(新) | 482,225.51 | -29,650,010 | 10,778,890.25 | 8,604,506.41 |
| 信用减值损失(新) | -7,135,752.07 | -32,031,533.05 | -13,555,936.56 | -13,741,308.26 |
| 其他收益 | 4,240,761.65 | 29,310,979.32 | 17,978,350.74 | 11,488,896 |
| 四、营业利润 | 52,067,500.64 | 203,271,353.27 | 197,307,297.13 | 191,549,753.11 |
| 加:营业外收入 | 264,280.92 | 4,388,453.22 | 4,959,038.76 | 3,614,697.46 |
| 减:营业外支出 | 1,216,730.84 | 32,575,842.94 | 22,492,144.1 | 24,555,916.9 |
| 五、利润总额 | 51,115,050.72 | 175,083,963.55 | 179,774,191.79 | 170,608,533.67 |
| 减:所得税费用 | 9,323,462.82 | 21,159,180.97 | 17,798,276.25 | 27,868,385.52 |
| 六、净利润 | 41,791,587.9 | 153,924,782.58 | 161,975,915.54 | 142,740,148.15 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 41,791,587.9 | 153,924,782.58 | 161,975,915.54 | 142,740,148.15 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 49,739,326.83 | 198,937,411.42 | 191,321,355.95 | 162,719,731.21 |
| 少数股东损益 | -7,947,738.93 | -45,012,628.84 | -29,345,440.41 | -19,979,583.06 |
| 扣除非经常损益后的净利润 | 49,664,685.87 | 166,797,183.34 | 156,762,062.38 | 135,889,558.76 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.08 | 0.34 | 0.33 | 0.28 |
| (二)稀释每股收益 | 0.08 | 0.34 | 0.27 | 0.28 |
| 八、其他综合收益 | -1,865,099.45 | -8,298,918.92 | -1,751,561.64 | 607,182.97 |
| 归属于母公司股东的其他综合收益 | -1,865,099.45 | -8,621,663.92 | -1,751,561.64 | 607,182.97 |
| 九、综合收益总额 | 39,926,488.45 | 145,625,863.66 | 160,224,353.9 | 143,347,331.12 |
| 归属于母公司股东的综合收益总额 | 47,874,227.37 | 190,315,747.5 | 189,569,794.31 | 163,326,914.18 |
| 归属于少数股东的综合收益总额 | -7,947,738.93 | -44,689,883.84 | -29,345,440.41 | -19,979,583.06 |
| 公告日期 | 2026-04-30 | 2026-04-30 | 2025-10-31 | 2025-08-30 |
| 审计意见(境内) | | 标准无保留意见 | | |